Lightspeed

Activity from announced rounds

Activity in this selectionUnited States · Mar 31, 2026 · Mar 1, 2026

Lightspeed Venture Partners invests from seed through growth in enterprise, consumer, fintech and healthcare companies, with a global investment platform.

Its sector teams approach different company-building problems: enterprise adoption, changes in consumer behaviour, financial infrastructure and unmet clinical needs. The partnership includes former founders and operators with domain experience, so the relevant team depends on the business being built rather than a single firm-wide industry thesis.

Lightspeed’s healthcare practice focuses on technologies that can improve patient outcomes. In fintech, its stated interests span the financial technology stack, including blockchain, rather than being limited to consumer banking applications.

Sources
Rounds participated in
7
Confirmed lead rounds
—
7 roles undisclosed
New companies
7
First participation on record · 0 follow-on
Funding in participating rounds
$1B
7 disclosed · full round size, not this investor’s share

By stage

Series B3
Series C+2
Seed1
Series A1

By primary sector

Fintech2
Healthtech2
Defense tech1
Developer tools1
Hardware1

By country

United States7

Rounds

7 in this selection
ScaleOps

Provides autonomous cloud and AI infrastructure resource management platform

$130MSeries C
Role not disclosed
Neon

Allows people to monetize their personal data

$25MSeed
Role not disclosed
Doctronic

Provides AI-powered personalized health insights and connects users to licensed providers instantly

$40MSeries B
Role not disclosed
Nexthop AI

Provides highly efficient AI networking solutions for hyperscale data centers

$500MSeries B
Role not disclosed
Axiom Trust Company

Axiom Trust Company provides professional trust administration for families and beneficiaries.

$11.8MSeries A
Role not disclosed
Nominal

Offers software for hardware engineers to test designs

$80MSeries B+
Role not disclosed
Science Corporation

Develops brain-computer interface retinal implants to restore vision in patients with retinal diseases

$230MSeries C
Role not disclosed